Avita Medical Names Michael Perry CEO, Succeeding Adam Kelliher - Quick Facts

Regenerative medicine company Avita Medical Limited (AVH.AX, AVMXY) Friday said it has appointed Michael Perry as its new Chief Executive Officer. The appointment is effective immediately. He succeeds Adam Kelliher, who resigned after two years of service.

According to the firm, its board determined that Avita's achievement of US-focused milestones will largely drive company value and as such, a decision was made to retain a US-based chief executive to optimize shareholder value. London-based Kelliher has elected not to relocate to the US and has resigned from his position, but will remain a consultant to the board of directors.

Perry has been an Avita non-executive director since February 2013. He was Senior Vice President and Chief Scientific Officer of Global Business Development and Licensing for Novartis AG.

From 2014-16, he served as Chief Scientific Officer of Novartis' Cell and Gene Therapy Unit. Prior to that, he was Vice President of the Inegtrated Hospital Care Franchise and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a US affiliate of Switzerland-based Novartis AG.

Previously, he was the Global Head of R&D for the Bioscience Division of Baxter Healthcare, President and CEO of Cell & Gene Therapy for Novartis subsidiaries Systemix Inc. and Genetic Therapy Inc., among other roles.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Motors will start replacing defective battery modules in Chevrolet Bolt EVs and EUVs with new modules. The replacement battery modules will be shipped to dealers as soon as mid-October, the automaker said in a statement. CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million...
Follow RTT